Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

...

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

...

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

...

A21 Launches Host Applications for Walk for Freedom 2024

A21 Launches Host Applications for Walk for Freedom 2024

...

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

...

Space Tea Set to Attend Natural Products Expo West 2023

Space Tea Set to Attend Natural Products Expo West 2023

Natural Products Expo West is the leading trade show in the natural, organic and healthy products industry, drawing buyers from retailers of all sizes......

menu
menu